A
Alcista
Alcista · 25%DYN
$9.00
Precio del escenario
$15.230
+1.048 (+6.88%)Al cierre
Loading chart…
- Máximo
- 15.375
- Apertura
- 14.480
- Precio medio ponderado por volumen
- 15.03
- Volumen
- 3.35M
- Capitalización
- 3.52B
- Mínimo
- 14.480
- Importe
- 50.29M
- EV/EBITDA, TTM
- 0.00
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.
Análisis de IA of Dyne Therapeutics, Inc (DYN)
VenderDyne Therapeutics is not a good buy right now due to its current price of $14.25, which is significantly below the analyst price targets of $30 and $32. The RSI is at 24.074, indicating the stock is oversold, but the negative sentiment from recent trial failures and a 5-day change of -14.36% raises concerns about its short-term viability. The main risk is the company's ongoing losses, with a net income of -178,556,000 USD in Q2 2026, which could further depress stock prices.
Recomendaciones de analistas (8)
+158.24% de potencial alcista
Comprar
4 Comprar
4 Mantener
0 Vender
Actual: 15.23
Mínimo
17.00
Promedio
39.33
Máximo
60.00
H.C. Wainwright
Comprar
$32
2026-09-30
H.C. Wainwright
2026-09-30
Precio objetivo
$32
Comprar
Piper Sandler
Sobreponderar
$47
2026-09-29
Piper Sandler
2026-09-29
Precio objetivo
$47
Sobreponderar
RBC Capital
Superar al mercado
$30
2026-09-09
RBC Capital
2026-09-09
Precio objetivo
$30
Superar al mercado
Morgan Stanley
Sobreponderar
$36
2026-09-09
Morgan Stanley
2026-09-09
Precio objetivo
$36
Sobreponderar
Baird
Superar al mercado
$26
2026-09-09
Baird
2026-09-09
Precio objetivo
$26
Superar al mercado
Métricas de valoración
El PER previsto actual de Dyne Therapeutics, Inc (DYN) es 0.00, frente a su media de 5 años de -5.06.
Escenarios de precio de Alphio AI para DYN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con DYN en cartera
Cronología de eventos
Noticias
9.009-30NASDAQ.COMDyne Therapeutics Releases Clinical Data on Z-basivarsen for Myotonic Dystrophy
9.009-30NASDAQ.COMDyne Therapeutics Reports Positive DM1 Trial Data
9.509-09stocktwitsDyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure
2.009-08stocktwitsNovartis Faces Setback in DM1 Drug Trial
8.509-03NewsfilterDyne Therapeutics Advances DMD Treatment Research with New Therapies
Preguntas frecuentes sobre DYN, respondidas por Alphio AI
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Dyne Therapeutics is not a good buy right now due to its current price of $14.25, which is significantly below the analyst price targets of $30 and $32. The RSI is at 24.074, indicating the stock is oversold, but the negative sentiment from recent trial failures and a 5-day change of -14.36% raises concerns about its short-term viability. The main risk is the company's ongoing losses, with a net income of -178,556,000 USD in Q2 2026, which could further depress stock prices.
8 analysts cover DYN: 4 rate it Buy, 4 Hold and 0 Sell. The average price target is 39.33.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.